Literature DB >> 11063835

Complement activation by titin and ryanodine receptor autoantibodies in myasthenia gravis. A study of IgG subclasses and clinical correlations.

F Romi1, G O Skeie, C Vedeler, J A Aarli, F Zorzato, N E Gilhus.   

Abstract

To elucidate the mechanism of immune damage caused by titin and ryanodine receptor (RyR) autoantibodies in myasthenia gravis (MG), we studied the complement-activating capacity and the IgG subclass distribution of these autoantibodies in sera from 49 MG patients. Complement activation occurred in 38 out of 49 titin antibody positive sera, and in 14 out of 21 RyR antibody positive sera. The titin antibodies occurred only in the IgG 1 and IgG 4 subclasses, whereas the RyR antibodies occurred in all four IgG subclasses but with IgG 1 predominance. Complement-activating RyR antibodies occurred with higher frequency in sera of thymoma MG than of late-onset MG. RyR IgG 1 antibodies occurred more often in severe MG than in mild and moderate disease groups. Mean total IgG and IgG 1 titin and RyR antibody titers fell during long-time patient observation together with an improvement of the MG symptoms.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11063835     DOI: 10.1016/s0165-5728(00)00394-5

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  8 in total

1.  Effect of complement and its regulation on myasthenia gravis pathogenesis.

Authors:  Linda L Kusner; Henry J Kaminski; Jindrich Soltys
Journal:  Expert Rev Clin Immunol       Date:  2008-01       Impact factor: 4.473

Review 2.  Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review.

Authors:  Jayne L Chamberlain; Saif Huda; Daniel H Whittam; Marcelo Matiello; B Paul Morgan; Anu Jacob
Journal:  J Neurol       Date:  2019-09-03       Impact factor: 4.849

3.  Cardiac troponin T and autoimmunity in skeletal muscle aging.

Authors:  Tan Zhang; Xin Feng; Juan Dong; Zherong Xu; Bo Feng; Karen M Haas; Peggy M Cawthon; Kristen M Beavers; Barbara Nicklas; Stephen Kritchevsky
Journal:  Geroscience       Date:  2022-01-15       Impact factor: 7.581

Review 4.  Muscle autoantibodies in myasthenia gravis: beyond diagnosis?

Authors:  Matthew N Meriggioli; Donald B Sanders
Journal:  Expert Rev Clin Immunol       Date:  2012-07       Impact factor: 4.473

5.  Three types of striational antibodies in myasthenia gravis.

Authors:  Shigeaki Suzuki; Kimiaki Utsugisawa; Yuriko Nagane; Norihiro Suzuki
Journal:  Autoimmune Dis       Date:  2011-07-17

6.  Efficacy and safety of double-filtration plasmapheresis treatment of myasthenia gravis: A systematic review and meta-analysis.

Authors:  Chaoying Liu; Peng Liu; Mei Ma; Hongxia Yang; Guoyan Qi
Journal:  Medicine (Baltimore)       Date:  2021-04-30       Impact factor: 1.817

7.  Eculizumab improved weakness and taste disorder in thymoma-associated generalized myasthenia gravis with anti-striational antibodies: A case report.

Authors:  Eiichiro Amano; Shinichi Otsu; Shigeaki Suzuki; Akira Machida
Journal:  eNeurologicalSci       Date:  2019-01-07

8.  Chorea and Parkinsonism with Elevated Striational Antibody.

Authors:  Harsh V Gupta; Heather Barnes; Fatma A Radhi; Yasir Jassam
Journal:  Ann Indian Acad Neurol       Date:  2020-02-25       Impact factor: 1.383

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.